Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04316572
Other study ID # S-923/2019
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 24, 2020
Est. completion date November 18, 2022

Study information

Verified date July 2023
Source Heidelberg University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Even in Western health care systems, most people with mental disorders, including those with severe and chronic disorders, are treated solely by their general practitioner (GP). Notably, the accessibility of mental health specialist care is mainly complicated by (a) long waiting times for specialists, (b) long travel distances to specialists, particularly in rural and remote areas, (c) patients' reservations about mental health specialist care (including fear of being stigmatised by seeking such care). To mitigate those barriers, technology-based integrated care models have been proposed. The purpose of this study is to measure the effectiveness of a mental health specialist video consultations model versus treatment as usual in patients with depression or anxiety disorders in primary care. In an individually randomized, prospective, two-arm superiority study with parallel group design, N = 320 patients with anxiety and/or depressive disorder will be recruited in GP practices.


Description:

The purpose of this study is to measure the effectiveness of a mental health specialist video consultations model versus treatment as usual in patients with depression or anxiety disorders in primary care. In total, the investigators plan to enrol 320 patients who will be randomly allocated to the experimental condition (mental health specialist video consultations) or the control condition (treatment as usual from their GP) in a 1:1 ratio. General practitioners will recruit patients during their regular clinic hours. If the patient is interested in participation, the patient will receive the informed consent form and the baseline questionnaire from the GP. The practice team will send the patient's contact details to the study team who will screen the patient with respect to the eligibility criteria. Patients will be randomly allocated to one of the two study conditions (video consultation model vs. treatment-as-usual, TAU) in a 1:1 ratio by central randomisation. The evaluation of the primary outcome will be performed according to the intention-to-treat principle. The health economic evaluation will be carried out from the perspective of society. A cost-effectiveness and a cost-utility analysis will be carried out.


Recruitment information / eligibility

Status Completed
Enrollment 376
Est. completion date November 18, 2022
Est. primary completion date May 24, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - at least one of the following psychological conditions i) at least moderately severe depression, defined as a PHQ-9 score of 10 or greater with either item one and/or two being endorsed, ii) at least moderately general anxiety disorder, defined as a Generalized Anxiety Disorder (GAD)-7 score of 10 or greater, or iii) exceeding the cut off of 11 points of the combined anxiety and depression score (PHQ-ADS) - currently no or as yet insufficient treatment (psychotherapy, psychopharmacotherapy, or both) or difficulty with adherence - capable of giving consent - written informed consent Exclusion Criteria: - substance abuse/dependence that is likely to compromise intervention adherence - risk of endangerment to others and/or risk of self-endangerment - need for emergency medical treatment - acute psychotic symptoms - severe cognitive impairment or dementia - significant hearing and/or visual impairment - pregnancy in the = 2nd Trimester - prior experience with video consultations as part of the feasibility trial - insufficient German language proficiency

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
mental health specialist video consultation
The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual: Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics. Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary. Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment. Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner

Locations

Country Name City State
Germany Heidelberg University Heidelberg Baden-Wuerttemberg

Sponsors (2)

Lead Sponsor Collaborator
Heidelberg University Heinrich-Heine University, Duesseldorf

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of Negative Effects of Psychotherapy (INEP) unintended/adverse effects of the intervention 6 months after inclusion, 12 months after inclusion (not measured at baseline, patients in control condition fill in adapted version)
Other Normalisation MeAsure Development questionnaire (NoMAD) measurement of acceptance of newly introduced treatment models, 4 dimensions, range:1-5, lower score indicates greater acceptance of the intervention 6 months after inclusion, 12 months after inclusion (measured in GPs and study therapists only)
Primary The Patient Health Questionnaire Depression and Anxiety Scale (PHQ-ADS) composite measure of depression and anxiety (range: 0-48 Points, higher score indicates more severly depressed/anxious) 6 months after inclusion
Secondary The Patient Health Questionnaire Depression and Anxiety Scale (PHQ-ADS) composite measure of depression and anxiety (range: 0-48 Points, higher score indicates more severly depressed/anxious) 12 months after inclusion
Secondary The Patient Health Questionnaire (PHQ-9) depressive symptom severity (range: 0-27 Points, higher score indicates more severly depressed) 6 months after inclusion, 12 months after inclusion
Secondary Generalized Anxiety Disorder Scale (GAD-7) anxiety symptom severity, range: 0-21, higher score indicates worse outcome 6 months after inclusion, 12 months after inclusion
Secondary Short-Form Health Survey 12 (SF-12) health related quality of life (two dimensions: physical and mental quality of life, ranges: 0-100, higher score indicates higher quality of life 6 months after inclusion, 12 months after inclusion
Secondary Recovery Assessment Scale (RAS-G) self-reported mental health recovery, five dimension: 1) Goal and success orientation, 2) No domination by Symptoms, 3) Personal confidence and hope, 4) Reliance on others, 5) Willingness to ask others for help, ranges 1-5, higher score indicates better outcome 6 months after inclusion, 12 months after inclusion
Secondary Somatic Symptom Disorder-B Criteria Scale (SSD-12) self-reported somatisation, range: 0-48, higher score indicates worse outcome 6 months after inclusion, 12 months after inclusion
Secondary Patient Assessment of Chronic Illness Care (PACIC) patients' satisfaction with the care of their chronic disease, range: 1-5, higher score indicates higher satisfaction 6 months after inclusion, 12 months after inclusion
Secondary EQ-5D health related quality of life for health economic Evaluations, 5 dimensions: 1) Mobility, 2) Self-Care, 3) Usual Activities, 4) Pain/Discomfort, 5)Anxiety/Depression 6 months after inclusion, 12 months after inclusion
Secondary Questionnaire for the Assessment of Medical and non Medical Resource Utilisation in Mental Disorders (FIMPsy) self reported use of medical and psychosocial services for health-economic evaluation 6 months after inclusion, 12 months after inclusion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A